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Abstract 
Breast cancer is the third most common cancer in Canada. Even though the morbidity 
and mortality rates have reduced in recent years because of early diagnosis and improved 
treatments, new treatment methods or therapeutic agents are still needed to deal with cases 
such as low response rates with triple negative breast cancer, rapid drug resistance, and side 
effects caused by breast cancer treatment.  
 
Sphingolipids have been reported to play an important role in breast cancer 
tumorigenesis. Sphingosine-1-phosphate (S1P), a pleiotropic lysophospholipid mediator, can 
regulate S1P receptor (S1PR)-dependent or S1PR-independent cell proliferation, apoptosis, 
autophagy, migration, survival, angiogenesis, and differentiation. Previous studies from our 
laboratory have shown that S1P can selectively cause cell death in breast cancer cell lines 
MDA-MB-231 and MCF-7. 
 
Our previous studies have shown that S1P exhibits synergistic effects with docetaxel, 
doxorubicin, and cyclophosphamide in human breast cancer MDA-MB-231 and MDA-MB-361 
cells. Since carboplatin is a commonly prescribed DNA alkylating agent and approved for 
advanced breast cancer, I investigated whether S1P or S1PR1 antibody can enhance the 
cytotoxic effect of carboplatin towards human breast cancer MCF-7, SK-BR-3, and MDA-MB-
231 cells.   
 
In this study, S1PR1 antibody was shown to exhibit cytostatic effect against the MCF-7, 
SK-BR-3 and MDA-MB-231 cell lines.  Co-administration of 4,000 ng/mL of the S1PR1 antibody 
not only potentiated the cytotoxicity of carboplatin towards the MDA-MB-231 cells but also 
increased the anti-proliferative effect of S1P towards SK-BR-3 cells.  Furthermore, we showed 
that co-administration of S1P did not sensitize the MCF-7, SK-BR-3 and MDA-MB-231 cells 
towards carboplatin. In the future, co-administration of 4,000 ng/mL S1PR1 antibody with 
carboplatin, as well other chemotherapy drugs such as docetaxel, paclitaxel and doxorubicin, 
will be evaluated against more breast cancer cell lines, and the mechanism on how S1PR1 
antibody enhances cytotoxicity of carboplatin on breast cancer cells will be studied. 
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Introduction 
Sphingosine-1-phosphate (S1P) is a common product of sphingolipid catabolism and an 
important bioactive sphingolipid metabolite.  It exerts its biological functions both intracellularly 
and extracellularly to regulate various physiological and pathophysiological processes 1–3.  The 
intracellular function of S1P is not clearly understood.  There is evidence showing that S1P acts 
as an intracellular messenger to regulate cell growth, invasion and apoptosis 4–6.  The 
extracellular function of S1P has been well studied, and S1P employs an “inside-out” signaling 
mode for its biological functions 7–10.  Briefly, S1P is first synthesized inside cells, and then 
transported out of the cells to interact with a family of five G protein-coupled sphingosine-1-
phosphate receptors (S1PR1-5) 9,10. S1P promotes cell proliferation and survival, inhibits cell 
apoptosis, and enhances angiogenesis via binding S1PR1 and S1PR3 9–12.  However, upon 
binding S1PR2, S1P inhibits cell proliferation and survival and induces cell apoptosis 9,10,13,14. 
Extensive studies have shown that the S1P-S1PR signaling axis plays an important role in 
cancer development and progression9,10. Furthermore, antagonism of S1PR1 by FTY720, a 
potent immunomodulator, caused internalization and desensitization of S1PR1 and inhibited 
tumor-associated angiogenesis 15.  Thus, downregulation of the S1P-S1PR1 signaling pathway 
would likely be an effective option to impede cancer development and progression. 
 
In addition, platinum-based chemotherapy drugs are a family of alkylating agents widely 
used to treat different types of cancer. However, breast cancer does not respond well towards 
platinum-based drugs. Carboplatin, usually in combination with other chemotherapy drugs, is 
the only platinum-based drug approved to treat advanced-stage breast cancer 16,17.  Since 
antagonism of S1PR1 has been observed to enhance the efficacy of doxorubicin 15,18, we 
decided to evaluate whether the S1PR1 antibody could potentiate the cytotoxic effect of 
carboplatin towards human breast cancer MCF-7, SK-BR-3 and MDA-MB-231 cells.   
 
  
  
 
2 
1 Breast cancer 
Breast cancer is the third most common cancer in Canada, accounting for 13% of all 
cancers and 25% of cancers in women in 2016.19 Although clinical outcome has been 
significantly improved for the breast cancer patients, mortality and morbidity rates remain high 
for late-stage breast cancer.20 Furthermore, for triple-negative breast cancer (TNBC) patients 
who even respond to chemotherapy treatment, the median overall survival still remains less 
than two years.21 
 
1.1 Breast cancer development 
Breast cancer commonly refers to breast adenocarcinoma, which accounts for 95% of 
all breast cancer. Normal human breast is a modified, specialized apocrine gland localized on 
the anterior chest wall overlying pectoralis major and minor muscles.22 As shown in Figure 1, it 
includes mammary glands and connective tissue stroma. The connective tissue stroma is a 
supportive structure that surrounds the mammary glands. It includes fibrous and fatty 
components.22 Breast cancer starts typically from cells of the breasts (mostly cells in the milk 
duct and lobules) losing genomic stability such as elevation of oncogene expression and 
silencing of tumor suppressor genes.  Although extensive efforts have been made to 
understand how breast carcinogenesis is initiated, there is still no consensus explanation for it. 
One hypothesis is "a sequential progression of proliferative changes places the breast at 
progressively increased risk for invasive carcinoma”.11  
 
Environmental and biological factors can initiate the development of the breast cancer 
by causing change and mutation of DNA molecules in breast cells. For example, radiation 
exposure and cigarette smoking can lead to mutations in the breast cell DNA molecules, and 
people with inherited mutated genes like BRCA1 and BRCA2 have a much higher chance of 
developing breast cancer.24 Also, epidemiological studies have established numerous risk 
factors for breast cancer.25,26 For instance, early menarche, late menopause, and nulliparity are 
all associated with increased risk of breast cancer.25 
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Figure 1: Cross-section scheme of the human mammary gland. 1) Chest wall; 2) 
Pectoralis muscles; 3) Lobules; 4) Nipples; 5) Areola; 6) Milk duct; 7) Fatty tissue (part of the 
stroma); 8) Skin.27 No copyright required. 
 
1.2 Molecular breast cancer subtypes 
Breast cancer is a heterogeneous disease. It can be divided into different subtypes 
depending on the molecular profile, histopathological staining and clinical classification, and 
associates with different prognostic and therapeutic implications. Based on gene expression 
profiling, breast cancer is classified into five biologically distinct intrinsic subtypes: luminal A, 
luminal B, human epidermal growth factor 2 (HER-2), basal-like, and normal-like subtype.28 
Luminal A subtype is breast cancer tumors with estrogen receptor (ER)-positive, progesterone 
(PR)-positive or PR-negative, HER2-negative, and low proliferating cell nuclear antigen (Ki67) 
index in immunohistochemistry.28 It tends to have a higher expression of ER-related genes and 
a lower expression of proliferative genes compared with luminal B.29–31  In addition, luminal A 
subtype shows to have the best prognosis and has significantly lower recurrence rate.29–31 
Luminal B subtype, in immunohistochemistry, is breast cancer tumors with ER-positive, HER2 
negative and high Ki67 or ER and HER2 positive.28 Compared to luminal A subtype, luminal B 
shows better response to adjuvant chemotherapy, but less sensitive to endocrine therapy.28 
HER2 subtype, most of which are associated with significantly upregulated expression of HER2, 
is often associated with nodal metastasis.32 Basal-like subtype which tends to have no 
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expression of ER, PR, and HER2, has a higher probability of metastasis and death from the 
progressive disease compared with other subtypes.32 Triple-negative breast cancer (TNBC) is 
characterized by lacking expression of ER, PR, and HER2. Therefore, most of TNBC could be 
classified into basal-like subtype, but not all the basal-like breast cancer subtypes possess 
triple-negative phenotype.32 The normal-like subtype is poorly characterized and has been 
grouped into the classification of intrinsic subtype with fibroadenomas and normal breast 
samples.32 They do not express ER, PR, and HER2; therefore, this subtype could also be 
classified as triple-negative. However, due to low expression of keratin 5 (CK5) and epidermal 
growth factor receptor (EGFR), they are not generally considered as basal-like breast cancer.32 
There are few studies on normal-like breast cancer, and the clinical significance of this subtype 
remains undetermined.28 This classification of breast cancer subtypes helps to divide breast 
cancer patients into different groups with distinct tumor morphologies and clinical outcomes.33 
 
1.3 Treatment 
Breast cancer treatment normally includes the following options: surgery, radiation 
therapy, chemotherapy, hormonal therapy, and targeted therapy. The prognosis and treatment 
options of breast cancer are generally based on tumor-node-metastasis (TNM) staging,34 
lymphovascular spread, histologic grade, hormone receptor status, HER2 overexpression, 
comorbidities, and patient menopausal status and age.35 The typical treatment options for 
breast cancer are summarized in Table 1. Historically, there was only one option for breast 
cancer treatment – surgery; however, it could not prevent subsequent recurrences and breast 
cancer-related deaths.35 Therefore, breast-conserving treatment and systemic therapy were 
used to treat breast cancer.36 Nowadays, most females with breast cancer will be treated with 
adjuvant systemic therapy which may include endocrine manipulation, chemotherapy, biologic 
therapy, or their combination.36 Among different therapies, surgery is the primary method to 
treat breast cancer. It contains either breast-conserving surgery following preoperative needle 
localization of the micro-calcifications or total mastectomy.37 Radiation therapy is a treatment 
that uses the high dose of radiation to damage DNA and cell membranes of cancer cells.38 
Hormonal therapy uses competitive antagonists to block hormone receptors on the cell surface 
such as ER or inhibitors of hormones synthesis .39 
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Table 1. Typical treatments for breast cancer by stage35 
  Adjuvant therapy 
Cancer Stage Primary treatment 
Hormone 
receptor 
negative 
Hormone 
receptor 
positive 
HER2 
overexpression 
Stage 0: Lobular 
carcinoma 
no - - - 
Stage 0: Ductal 
carcinoma in situ 
Surgery (breast-
conserving or 
mastectomy) 
- - - 
Stage I and II 
Induction 
chemotherapy, 
breast-conserving 
surgery, radiation 
therapy 
Chemotherapy 
Chemotherapy, 
endocrine therapy 
Chemotherapy 
and trastuzumab 
Stage III: Locally 
advanced 
Noninflammatory 
Induction 
chemotherapy, 
followed by breast-
conserving surgery 
and radiation therapy 
Induction 
chemotherapy 
 
Induction 
chemotherapy 
and post-
operative 
endocrine therapy 
Induction 
chemotherapy 
and postoperative 
trastuzumab Stage III: Locally 
advanced 
Inflammatory 
Induction 
chemotherapy, 
followed by 
mastectomy and 
radiation therapy 
Stage IV 
Radiation therapy or 
bisphosphonates for 
bone pain 
Chemotherapy 
Endocrine 
therapy 
with/without 
chemotherapy 
Trastuzumab 
with/without 
chemotherapy 
Note: Permission to use this table is granted by the American Academy of Family Physicians. 
 
1.3.1 Chemotherapy 
Chemotherapy is vital for breast cancer treatment (Table 1). During the last decade, 
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significant progress has been made in cytotoxic chemotherapy for advanced and early-stage 
breast cancer treatment.21  Chemotherapy is a treatment using anti-cancer drugs to destroy 
dividing cancer cells or stop their division.40 For patients diagnosed with HER2 positive 
metastatic breast cancer, trastuzumab alone or with chemotherapy will always be considered 
as first-line treatment.41 For patients with hormone receptor-negative plus HER2-negative 
metastasis breast cancer, single-agent chemotherapy or combination chemotherapy of 
paclitaxel with bevacizumab will be given as first-line treatment.41 For patients with hormone 
receptor-positive and HER2-negative breast cancer, endocrine treatment will first be considered 
as first-line therapy before chemotherapy.41,42 The most commonly used first-line chemo-drugs 
are anthracyclines (such as doxorubicin, epirubicin, pegylated liposomal doxorubicin) and 
taxanes (such as paclitaxel, docetaxel, and albumin-bound paclitaxel).41–43 Taxanes are also 
the most effective second-line treatment for metastatic breast cancer patients who have 
developed drug resistance for anthracyclines.44 If patients fail both anthracycline and taxane 
treatments, other chemo-drugs that possess different mechanisms to destroy cancer cells will 
be considered as second-line or later-line chemotherapy treatment such as capecitabine, 
gemcitabine, ixabepilone, and vinorelbine.44  
 
1.3.1.1 Carboplatin 
Carboplatin is a chemo-drug used to treat different kinds of cancer specifically for testis, 
ovary, head, neck and small cell lung cancer.45 It is classified as a DNA alkylating agent that 
can covalently link to DNA bases and form DNA adducts. Platinum-based chemotherapy is not 
commonly used in breast cancer treatment, but it could develop into a highly important new 
treatment modality to TNBC especially against two TNBC subgroups – basal-like 1 and 2, which 
are characterized by high expression levels of DNA-damage response genes.16,17 Based on its 
sensitivity against TNBC, it is possible that platinum-based drugs are used to predict the in vivo 
situation for breast cancer patients.16 Currently, carboplatin is the only platinum-drug approved 
for breast cancer treatment by FDA. 
 
Carboplatin was developed to overcome the severe side effects of cisplatin.45 Cisplatin, 
one of the platinum-drugs, is an effective antitumor agent. Studies have shown that vinorelbine 
in combination with cisplatin could be used as salvage treatment for patients with metastatic 
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breast cancer and developed resistance towards anthracyclines or taxanes.41,46,47 Although 
carboplatin has fewer side effects than cisplatin, it is significantly less potent compared with 
cisplatin and is still associated with the risk of cumulative toxicities that make it limit for cancer 
treatment.45 Therefore, finding a method to improve the potency of carboplatin is essential for 
the development of more treatment options for breast cancer patients. 
 
1.3.2 Targeted therapy 
Targeted therapy is a treatment that targets the overproduced growth-promoting proteins 
of breast cancer cells.48 It has less severe side effects compared with traditional 
chemotherapy.48 Along with the greater understanding of the biology of breast cancer, more 
molecular targets have been found and more novel therapies developed.49 Examples include 
inhibitors of estrogen receptor (ER), human epidermal growth factor receptor 2 (HER2), 
extracellular-signal regulated kinase (ERK), protein kinase B (Akt) and phosphoinositide 3-
kinase (PI3K).49 Among these targets, ER and HER2 are well-established therapeutic targets 
for breast cancer. Agents that target ER, such as tamoxifen and aromatase inhibitors, and 
HER2, such as trastuzumab and pertuzumab, are among the most successful cancer 
therapeutics.50 In Figure 2, the ER and PI3K signal pathways are shown to regulate cell 
proliferation and survival.  Currently, these targeted methods are commonly used in 
combination with chemotherapy.  
 
  
 
8 
 
Figure 2. ER pathway and PI3K signaling pathway. Agents used in targeted therapy can 
inhibit the proteins as the signs in red show. 
 
1.3.3 Challenges for breast cancer treatment 
The overall 5-year relative survival rate for female breast cancer patients has improved 
because of the advances in treatment and earlier detection as the result of increased 
awareness and widespread use of mammography.51  However, new treatment methods or 
treatment agents are still needed because of the low response rates by triple negative breast 
cancer, drug resistance, and side effects caused by breast cancer treatment.  
 
For breast cancer patients, based on biological, clinical, patient-specific factors, different 
chemotherapy agents are available for them. However, the response rates of these drugs are 
not ideal, especially for metastatic breast cancer. For example, anthracyclines and taxanes, the 
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chemotherapeutic agents possessing a dominant position in breast cancer treatment, the 
response rate as the first-line therapy for metastatic breast cancer is 38% and 33%, 
respectively.41,52  
 
Drug resistance is another issue that will arise during breast cancer treatment. At the 
start, agents used in systemic therapy are active in 90% of primary breast cancer and 50% of 
metastases.53 After a variable period, though, cancer progresses, and drug resistance is 
expected to occur.53 Drug resistance is the cause for more than 90% of treatment failure against 
metastatic diseases.54  One mechanism for drug resistance is related to ATP binding cassette 
(ABC) transporters including P-glycoprotein (P-gp) and multi-drug-resistance proteins (MRPs) 
which are responsible for transferring drug molecules such as anthracyclines and taxanes out 
of the cells.54 Therefore, increased expression of ABC transporters might be found in cells that 
have developed chemo-resistance. Although several inhibitors of ABC transporters are 
available, their therapeutic results are not satisfactory.54 Therefore, discovering and developing 
new agents that can overcome the mechanisms of multi-drug resistance is essential for 
improved breast cancer treatment.54 
 
Short-term and long-term health effects caused by breast cancer treatment remain a 
concern.51 For example, studies have shown that 25% - 60% of women develop chronic pain 
after breast cancer surgery.55,56 Chemotherapy treatment can cause impaired fertility and 
menopause-related concerns such as osteoporosis.57 Most often, chemotherapy with taxanes 
leads to neuropathy that can persist long after treatment ends.58 Also, breast cancer survivors 
may suffer from cognitive impairments and chronic disease because of the treatments.51 
Therefore, agents with fewer side effects are needed so that better quality of life can be 
achieved after breast cancer treatment. 
 
2 Sphingolipids 
 Sphingolipids, a type of lipid found in cell membranes, play an essential role in a wide 
array of cellular activities by participating in various membrane functions and signaling 
events.59–61  They are found in all eukaryotic cells, especially plentiful in the plasma membrane 
and related cell membranes, such as Golgi membranes and lysosomes.62 In general, the 
  
 
10 
chemical structure of sphingolipids is based on an 18-carbon amine alcohol backbone 
(sphingoid base), linked to a fatty acid molecule via an amide bond.63 Sphingolipids comprise 
a large family of members, including sphingosine-1-phosphate (S1P), which regulates cellular 
signal transduction, contributing to the determination of cell fate.64  
 
Sphingolipid metabolism wields a double-edged sword to cell fate.61,64,65 In response to 
stressful conditions or cytotoxic therapy, ceramide can trigger activation of signals that affect 
intrinsic and extrinsic apoptotic pathways and cell cycle control, while simultaneously inhibiting 
signaling events that promote cell growth and survival mediated by the Akt pathway.64 S1P can 
promote or inhibit cell growth, survival, angiogenesis, and apoptosis depending on the cell 
context (S1PRs expression status and the availability of downstream signaling 
pathways).61,64,65 
 
2.1 Sphingolipid metabolism 
Two pathways exist to synthesize sphingolipids inside cells -- de novo biosynthesis and 
recycling of sphingomyelin (Figure 3). De novo synthesis begins with condensation of serine 
and palmitoyl-CoA to form 3-ketosphinganine, which is catalyzed by serine palmitoyltransferase 
(SPT) in the endoplasmic reticulum.66 Then, 3-ketosphinganine is reduced to form sphinganine, 
followed by incorporation of a fatty acyl-CoA to form dihydroceramide in a reaction catalyzed 
by ceramide synthase activity.67 L-Alanine or L-glycine, two other kinds of amino acid-based 
sphingolipids, are reported to form 1-deoxy- or 1-deoxy-methyl-derivatives, respectively.68,69 
Dihydroceramide can be converted to ceramide by a desaturase. Once synthesized, ceramide 
is transported to the Golgi apparatus to synthesize other sphingolipids.66 Since ceramide has 
low solubility in an aqueous environment, it needs the help of ceramide transfer protein (CERT) 
to transport from ER to Golgi apparatus.66 In Golgi, ceramide is transferred to sphingomyelins 
(SM) by sphingomyelin synthase and forms glucosylceramide by ceramide 
galactosyltransferase (CGT) or ceramide-1-phosphate (C1P) by ceramide kinase (CERK).66 
SM, however, can be hydrolyzed back to ceramide by sphingomyelinase (SMase).66 This is the 
second pathway to synthesize ceramide. Subsequently, ceramide could be deacylated into 
sphingosine (Sph) though ceramidases. Sphingosine-1-phosphate (S1P), the last sphingolipid 
in this cycle, is generated via direct phosphorylation of free sphingosine catalyzed by 
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sphingosine kinases (SK).66 S1P can be degraded to ethanolamine phosphate and 
hexadecenal by sphingosine-1-phosphate lyase (SPL) or convert back to sphingosine by 
sphingosine-1-phosphate phosphatase.66 
  
 
Figure 3. Sphingolipid metabolism. Ceramide (Cer) can be synthesized from de novo 
biosynthesis, which begins in the endoplasmic reticulum with serine and palmitoyl-CoA. Cer is 
transported to Golgi apparatus by ceramide transfer protein (CERT). In Golgi, Cer is further 
metabolized to sphingomyelin by sphingomyelin synthase or to ceramide-1-phosphate by 
ceramide kinase (CERK) or to complex glycosphingolipids. Sphingomyelin (SM) can be 
converted back to Cer by sphingomyelinase (SMase), which is the second way to synthesize 
Cer.  In the membranes, ceramide can be catalyzed by ceramidases to form sphingosine, which 
could be further phosphorylated to form sphingosine-1-phosphate (S1P) by sphingosine kinase 
(SK). S1P could be converted back to sphingosine by S1P phosphatase or degraded by S1P 
lyase (SPL). 
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2.2 Sphingosine-1-phosphate  
Sphingosine 1-phosphate (S1P), a vital sphingolipid metabolite, plays a crucial role in 
many physiological and pathophysiological processes, such as cell growth, angiogenesis, and 
migration.70 The chemical structure of S1P is shown in Figure 4. S1P is a common product of 
sphingolipid catabolism that can act directly on intracellular targets or be transported out of the 
cell and bind to its G protein-coupled receptors, sphingosine-1-phosphate receptors 1-5 
(S1PR1-5), on the cell surface.63 Depending on the cell type, location of the receptor, and the 
specific receptor subtype, S1P will cause cell responses that influence cell survival, proliferation, 
angiogenesis, chemo-resistance, and migration. 
 
Intracellular and extracellular S1P levels are always under tight control by several 
enzymes. Specifically, hydrolysis of the sphingolipid complex is controlled by 
sphingomyelinases and glycosidases.71 Subsequently, ceramidases can hydrolyze ceramide to 
produce sphingosine, a direct precursor of S1P by the action of sphingosine kinases.71 S1P is 
also regulated by enzymes responsible for its degradation (mainly S1P lyase).71 
 
Figure 4. Chemical structure of sphingosine-1-phosphate 
 
2.2.1 S1P inside-out signaling 
S1P inside cells cannot freely pass through the plasma membrane because its polar 
head group impedes passive diffusion. Consequently, to be transported outside of the cells, 
S1P needs the help of transporters. ATP-binding cassette (ABC) transporters and sphingolipid 
transporters 2 (Spns2) were found to assume this responsibility.7,72 Therefore, one way for S1P 
to exert its function after generation by SK1 is release from the cells and subsequent binding 
to its receptors on the cell surface through an autocrine, paracrine and/or endocrine manner. 7 
This process is called S1P inside-out signaling.7 
 
2.2.2 S1P axis 
The sphingosine-1-phosphate (S1P) axis refers to the signaling molecule S1P, its 
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receptors and its intracellular targets, as well as the proteins that synthesize, transport and 
degrade S1P.73 In the following section, the functions of different components in the S1P axis 
will be discussed. 
 
2.2.2.1 Sphingosine kinases  
There are two isoforms of sphingosine kinase, sphingosine kinase 1 (SK1) and 
sphingosine kinase 2 (SK2), which are members of diacylglycerol (DAG) kinase family.74 Even 
though they can produce the same product, their catalytic properties, subcellular locations, 
tissue distribution and expression pattern are different, which, in turn, determines their 
respective distinct or specific effects inside cells.63 
 
SK1, which contains 384 amino acids, is encoded by gene SPHK1 on chromosome 
17q25 with the highest mRNA expression level in lung, spleen, kidney and blood.75 It is mainly 
distributed within the cytoplasm.75 Through translocation to the plasma membrane where 
sphingosine resides, SK1 can enhance S1P production and extracellular release of S1P.76,77 
SK1 can be activated by numerous growth factors such as platelet-derived growth factor 
(PDGF), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and tumor 
necrosis factor- (TNF-), and by histamine, vitamin D, and steroid hormones.75 Previous 
studies suggest that SK1 and formation of S1P are related to the cell growth and survival.78 For 
example, VEGF can stimulate SK1 to produce S1P, which mediates VEGF-induced activation 
of Ras GTPase, followed by ERK activation and cell growth.78  Overexpression of SK1 in cells 
enhances cell survival and allows resistance to agents that can induce apoptosis.79 In addition, 
SK1 regulates cancer cell migration through receptor crosstalk.79 For example, in EGF-induced 
cell migration of MCF-7 cells, activating SK1 by platelet-derived growth factor (PDGF) signaling 
stimulated S1PR1 receptor by secreted S1P, inducing Rac GTPase activation.80,81 
 
SK2, which contains 618 amino acids, is encoded by gene SPHK2 on chromosome 
19q13.33 with the highest mRNA expression level in liver, kidney, brain, and heart.75 Unlike SK1 
that only uses sphingosine as the substrate, SK2, which is predominantly located in the nucleus 
or perinuclear region of the cells, utilizes a variety of sphingoid bases as substrates, such as 
dihydrosphingosine.82 Furthermore, SK2 possesses not only an overlapping role of SK1 in 
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promoting tumor development but also an opposing role in inducing apoptosis.78 SK2 was found 
to suppress growth and markedly enhance apoptosis that was independent of S1PRs.78 SK2 
contains a functional Bcl-2 homology 3 (BH3) domain, which may allow it to interact with Bcl-2 
family members to trigger apoptosis.78 This may be the mechanism for SK2 to induce cell 
apoptosis.78 All in all, overexpression of SK2 could lead to inhibition of cell growth and induction 
of apoptosis.4,83–85 
 
2.2.2.2 Sphingosine-1-phosphate lyase 
Sphingosine-1-phosphate lyase (SPL) is a single transmembrane protein that is 
exclusively localized to the endoplasmic reticulum. The activity of SPL depends on its cofactor 
pyridoxal-5’-phosphate (PLP), which is ubiquitously found in the ER except in platelets.75 SPL 
is responsible for irreversible degradation of phosphorylated sphingoid bases such as S1P, 
dihydrosphingosine-1-phosphate and phytosphingosine-1-phosphate to hexadecenal and 
phosphoethanolamine.66 Therefore, it can control the levels of bioactive sphingolipid 
metabolites. SPL may be vital for tissue development and associated with some diseases such 
as Sjögren–Larsson syndrome86.  
 
2.2.2.3 S1P receptors 
The extracellular function of S1P is related to its receptors (S1PR1-5) on the cell 
surface87–89. Through binding to different receptors, S1P can cause various downstream 
reactions. S1PRs belong to the G-protein coupled receptors superfamily. In the human body, 
the distribution sites of S1P receptors are summarized in Table 2. S1P receptors can couple to 
different G-proteins. For example, S1PR1 couples only with Gαi, whereas S1PR2 and S1PR3 
couple with Gαi, G12/13 and Gq.90 Depending on type and abundance of S1PRs, as well as their 
respective downstream signaling, S1P influences cell survival, cell proliferation, cell apoptosis, 
cell migration, angiogenesis, chemo-resistance, and other functions.87–89  
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Table 2: Distribution of different Sphingosine-1-Phosphate receptors91 
S1PR 
Distribution 
Tissue Cellular 
S1PR1 
Most tissues, highest in CD19+ B cells 
and cerebellum 
Plasma membrane, caveolae, 
cytoplasmic vesicles, nucleus, 
perinuclear region 
S1PR2 Most tissues Plasma membrane, cytoplasm 
S1PR3 
Highest in heart, lung, spleen, kidney, 
intestine, diaphragm 
Plasma membrane 
S1PR4 
Highly expressed in lymphoid tissues 
and blood cells, especially CD19+ B 
cells and lung 
N/A 
S1PR5 
Mostly in brain, skin and natural killer 
cells 
N/A 
Note: Permission to use this table is granted by the John Wiley and Sons. 
 
2.2.2.3.1 S1PR1 
S1PR1 is ubiquitously expressed in cells. As a pro-tumorigenic receptor, it promotes cell 
proliferation, survival, migration, angiogenesis, and metastasis (Figure 5).92–94 In addition, 
S1PR1 plays a vital role in tumor progression. 95 For example, the previous study has shown 
that S1PR1 is vital in mediating S1P-stimulated glioma cell proliferation.95 In S1PR1 knockdown 
mice, tumor growth is suppressed because of the lack of new blood vessel formation within the 
tumor.96 
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Figure 5. Major signaling pathways and functions of extracellular S1P by binding to 
S1PR1 on the cell surface. The activation of S1PR1 receptor can reduce AC level, stimulate 
PI3K, PLC and/or Ras GTPase protein, leading to activation of cell angiogenesis, cell survival, 
cell proliferation, cell differentiation, cell motility, cell adhesion, lymphangiogenesis, and 
reduction of cell apoptosis. 
 
With activation by S1P, S1PR1 can initiate different cell signaling pathways through 
coupling with Gi protein.97 It is capable of inhibiting adenylate cyclase (AC) activity, and 
subsequently, significantly reducing cyclic adenosine monophosphate (cAMP) level within the 
cells.95  S1PR1 signaling can also activate the PI3K/Akt pathway, eventually leading to 
angiogenesis and cell survival.98–100 The maintenance of the cell membrane integrity is through 
the phosphorylation of endothelial nitric oxide synthase (eNOS) or inhibition of glycogen 
synthase kinase 3 (GSK-3) to promote cell survival in endothelial cells.101,102 The activation of 
PI3K can also enhance cell adhesion and motility by stimulating a member of guanine 
nucleotide exchange factors (GEF), VAV1, and its downstream factors CDC42, RhoA and 
Rac.103 In addition, S1PR1 can work on the Ras-Raf-MEK-ERK pathway to increase cell 
proliferation and differentiation or to suppress cell apoptosis by inhibiting c-Jun N-terminal 
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kinases (JNKs).104 Moreover, phospholipase C (PLC) can be stimulated by S1PR1, inducing 
lymphangiogenesis because of the mobilization of calcium.105 Angiopoietin 2 (Ang2) can be 
secreted from the cells triggered by exogenous S1P via the S1PR1/Gi/PLC/calcium signaling 
pathway, then bind to Tie2 in an autocrine fashion to induce lymphangiogenesis alternatively.106 
Recently, a positive feedback loop was found between signal transducer and activator of 
transcription-3 (STAT3) and S1PR1.92,94 STAT3 was found to be a transcription factor for 
S1PR1.92 Activated S1PR1 upregulates the expression of interleukin 6 (IL-6), a pro-inflammatory 
cytokine crucial for STAT3 activation, inflammatory, and cell-mediated transformation, and 
tumor progression.98 Therefore, S1P-mediation activation of S1PR1 results in the activation of 
different signal transduction pathways to enhance cell survival, proliferation, cell motility, 
angiogenesis, and lymphangiogenesis and inhibit cell apoptosis.  
 
2.2.2.3.2 S1PR2 
S1PR2 can be an anticancer receptor or promote cancer growth receptor based on the 
G proteins it couples to and the available downstream reactions.91 S1PR2 is vital for normal 
body functions. In vivo studies of S1PR2 knockout mice showed that seizures were detected 
and occasionally fatal.107 Furthermore, S1PR2-deficient mice have decreased renal and 
mesenteric vascular resistance, indicating its function on vasculature.108 
 
As Figure 6 shown, S1PR2 can couple to Gai, Gq, or G12/13 proteins and activate different 
downstream reactions. Similar to S1PR1 activation, S1PR2 can cause AC activity and reduction 
in cellular cAMP levels via Gai.91 S1PR2 also activates Ras-Raf-MEK-ERK pathway through Gai, 
leading to elevation of cell proliferation.95 Also, S1PR2 can activate PLC to induce inositol 1,4,5-
trisphosphate (IP3) and Ca2+ mobilization, as well as increase cell lymphangiogenesis by Gai 
proteins.95 In bladder cancer, S1PR2 was shown to down-regulate tumor suppressor proteins 
such as breast carcinomas metastasis suppressor 1 (brms1).109 Therefore, S1PR2 was thought 
to be a receptor that can enhance tumorigenesis.  
 
S1PR2 can also mediate the stimulation of PLC and Ca2+ mobilization via Gq protein that 
can lead to the vascular contraction in some vascular beds, therefore regulates normal blood 
flow.110 
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Compared with Gq, S1PR2 prefers to couple to G12/13. Coupled with G12/13, S1PR2 can 
activate RhoA GTPase and inhibit Ras GTPase activity, causing reduction in cell migration and 
membrane ruffling.91 Activating Rho GTPase can lead to activation of Rho-associated protein 
kinase (ROCK) and phosphatase and tensin homolog (PTEN), a protein that can inhibit Akt 
activity by dephosphorylating phosphatidylinositol (3,4,5)-trisphosphate (PIP3), reducing cell 
proliferation.102 Therefore, S1PR2 is an anti-tumorigenic molecule and can hinder cells from 
distant metastasis. S1PR2 was reported to exist inside cells, and endogenous S1PR2 is solely 
responsible for mediating suppression of migration and invasion by S1P.14 
 
Figure 6. Major signaling pathways and functions of extracellular S1P by binding to 
S1PR2 or S1PR3 on the cell surface. S1PR2 and S1PR3 can couple to Gαi, G12/13 or Gq proteins. 
Through the activation of the Gαi protein, S1PR2 or S1PR3 can downregulate AC level, stimulate 
Ras, PI3K and/or PLC protein, leading to the upregulation of cell proliferation, cell angiogenesis, 
and cell lymphangiogenesis. By activating Gq protein, S1PR2 or S1PR3 activates PLC protein, 
causing activation of cell lymphangiogenesis. Coupled with G12/13 protein, S1PR2 or S1PR3 can 
inhibit cell survival, cell proliferation and cell migration via activating ERK and inhibiting Akt 
proteins. 
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2.2.2.3.3 S1PR3 
S1PR3 is less studied compared to S1PR1 and S1PR2. S1PR3 knockout in mice does 
not result in an obvious phenotype.111 As Figure 6 shown, S1PR3 can couple to Gαi, G12/13 and 
Gq. When coupling with Gαi, similar to S1PR1, S1PR3 reduces the cAMP level and activates 
Ras-Raf-MEK-ERK pathway, resulting in an increase in cell proliferation and an inhibition of 
apoptosis.95 With activation by S1P, S1PR3 can trans-activate different receptors.112–114 For 
example, in breast cancer, estrogen stimulation could cause S1PR3 to trans-activate EGFR and 
leads to an increase in cell proliferation.115  
 
Among G12/13 and Gq proteins, unlike S1PR2, S1PR3 prefers to couple with Gq protein, 
thus favoring PLC activation.95 Therefore, it is possible that the effect of S1P might be 
determined by the balance between S1PR2- and S1PR3- mediated signals.116 In gastric cancer 
cells, when the expression level of S1PR2 is higher than that of S1PR3, S1P inhibits cell 
migration and vice versa.116 Therefore, mostly S1PR3 was observed to elude pro-tumorigenesis 
functions as S1PR1 in tumor progression. 
 
2.2.2.3.4 S1PR4 and S1PR5 
S1PR4 is mainly expressed in the hematopoietic system. Its function inside the cells is 
not clear but S1PR4 knockout mice showed defects in dendritic cell differentiation and cytokine 
secretion.117 
 
S1PR5 is predominately expressed in the brain and within natural killer cells. Even 
though the function is under investigation, recent research suggests S1PR5 could inhibit 
migration and proliferation of esophageal cancer cells.118 
 
In summary, S1PR1-5 play crucial roles in various physiological and pathophysiological 
processes in human.  For breast cancer, it is usually associated with the functions of S1PR1-3.  
To get a better glimpse of whether S1PR1-3 indeed affects breast cancer patient’s survival, we 
extracted the Kaplan-Meier plots for survival versus mRNA expression level for S1PR1-3 from 
patients’ data deposited at the Human Protein Atlas (HPA) database (Figure 7).119  Surprisingly, 
the expression of S1PR1 does not exhibit any effect on the predicted patient survival probability 
  
 
20 
for breast cancer patients; whereas both S1PR2 and S1PR3 are favorable prognostic factors for 
breast cancer patient’s survival. As shown above, activation of S1PR1 can lead to cancer growth 
in both in vitro and in vivo experiments. Furthermore, S1PR1 antagonists such as FTY720, were 
shown to be able to inhibit tumor angiogenesis in vivo and enhance therapeutic efficacy of 
doxorubicin.18,120 Therefore, blocking S1PR1 with its antibody, associated with the exogenous 
administration of S1P, might lead to activation of S1P-S1PR2 and S1P-S1PR3 pathways, which 
might be a favorable option for better treatment outcome for breast cancer.  
 
 
Figure 7. Kaplan-Meier plot of patient survival probability versus mRNA expression 
level for S1PR1-3 based on breast cancer patients’ data deposited at the Human Protein Atlas 
database.119 URL for the images: https://www.proteinatlas.org/ENSG00000170989-
S1PR1/pathology/tissue/breast+cancer, https://www.proteinatlas.org/ENSG00000267534-
S1PR2/pathology/tissue/breast+cancer, https://www.proteinatlas.org/ENSG00000213694-
S1PR3/pathology/tissue/breast+cancer. Images available from v18.proteinatlas.org.  
 
2.2.3 S1P intracellular functions 
The intracellular function of S1P is not fully understood, but the evidence thus far 
suggests S1P is an intracellular messenger (Figure 8). Recent studies suggest that intracellular 
S1P produced by nuclear SK2 can directly bind to and inhibit histone acetylation 1/2 (HDAC1/2) 
which removes acetyl groups from histones to epigenetically regulate target genes and reduce 
their generation, such as IL-6 and TNF- in mouse lungs.121–123 S1P generated by SK1/2 can 
regulate amyloid-β (Aβ) by inhibiting BACE1 in Alzheimer’s disease (AD).124 Intracellular S1P 
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produced by SK1 was found to be a cofactor for TNF receptor-associated factor 2 (TRAF2), 
which can lead to polyubiquitination of receptor interacting protein 1 (RIP1) and activation of 
the NF-κB pathway to inhibit apoptosis.125 Besides, in mitochondria, S1P with prohibitin 2 
(PHB2), a protein localized on the inner mitochondrial membrane, shows vital roles in 
mitochondrial respiration.126  
 
In addition, S1PRs have been shown to localize inside the nucleus.4  It has been 
demonstrated that S1PR2 exists inside the nucleus and nuclear S1PR2 inhibits the growth of 
estrogen receptor-negative breast cancer cells.127 Furthermore, intracellular S1P produced by 
SK2 can bind to S1PR4, causing nuclear translocation of S1PR2, thereby promoting cell 
growth.127 As well, SK2-derived S1P mediates epidermal growth factor-induced cancer cell 
invasion via the activation of intracellular S1PR2.128 Recent studies demonstrate that S1P 
produced by SK2 can act as an acute ezrin-radixin-moesin (ERM) activator, which can facilitate 
signal transduction between the extracellular matrix and the cytosol,128 through its action on 
S1PR2.128  
 
Although much progress has been made for the intrinsic functions on improving cell 
survival, the anti-tumorigenesis effect of S1P has been shown to relate to S1P intrinsic 
functions.129 For example, Wang et al. found that exogenous administration of S1P inhibits the 
chemotactic motility of human breast cancer MCF-7 and MDA-MB-231.129 Through using caged 
S1P that could bypass cell surface receptors, it was further demonstrated that S1P inhibition of 
the motility was independent of the receptor and was associated with the intracellular action of 
S1P.129 
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Figure 8. Functions of intracellular S1P that have been discovered so far. S1P produced 
by SK1 inside the cells can inhibit apoptosis by activating NF-κB protein. S1P synthesized by 
SK2 can bind to PHB2 on the inner mitochondrial membrane and help maintain mitochondrial 
function on aspiration. It can also induce cell growth and cell invasion via S1PR2 inside the cells. 
 
2.2.4 S1P and breast cancer 
Evidence suggests SK1/2 and S1P produced by SK1 could work as tumor-promoting 
molecules, and their elevation has been observed in different types of cancer and tumor tissues. 
For breast cancer, compared with normal breast tissue, expression of SK1 was found to be 
elevated in breast cancer cells.61 Poor prognosis and promotion of metastasis are related to 
higher SK1 expression.61 For example, in MCF-7 breast cancer cells, overexpression of SK1 
enhanced estradiol-dependent tumor formation.130 Also, SK1 is a key regulator of breast cancer 
progression as SK1 was required for EGF-directed motility.80 EGF and EGFR downstream 
signaling has an essential role in the progression, invasion, and maintenance of malignant 
phenotype of breast cancer.80 Hence, down-regulating SK1 could reduce EGF- and serum-
stimulated growth and enhance sensitivity to doxorubicin, a potent chemotherapeutic agent.80 
For SK2, even though its connection with cancer is unclear, its down-regulation in MCF-7 
decreases G2-M arrest and enhances apoptosis induced by doxorubicin dramatically.84 In 
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mouse tumor model, SK2-deficient breast cancer cells impair its growth and indicate its function 
on cell growth.126,131 
 
S1P and SK2 also work as anti-tumorigenesis molecules. As mentioned above, SK2 was 
found to suppress growth and markedly enhance apoptosis that was independent of S1PRs.78 
Intracellularly, SK2-produced S1P could act as an endogenous HDAC inhibitor,132 suggesting 
a more sophisticated role of SK2 in cancer progression based on different epigenetic regulation 
contexts among different cell types.  
 
It is speculated that the anti-tumor function of exogenous S1P on breast cancer is due 
to its intracellular role. Other than studies by Wang et al.129, our previous studies showed that 
S1P could selectively induce cell apoptosis of breast cancer cells at a concentration higher than 
1µM.133  At these concentrations, both S1PR1 and S1PR2 were expected to be blocked by ligand 
saturation. S1P would accumulate inside the cells, induce apoptosis, and inhibit migration via 
its intracellular functions.  
 
2.2.5 S1P and chemo-resistance 
Although progress has been made in diagnosis and treatment of breast cancer in the 
past several decades, drug resistance and toxicity of therapy remain the primary causes for 
failure treatment of breast cancer.21,40,47,53 It has been shown that endogenous level of 
ceramides and S1P are essential to chemotherapy resistance.134 Alteration of ceramide 
accumulation can cause cancer cells to develop resistance towards chemotherapy.61 
Knockdown of glucosylceramide synthase (GCS), which synthesizes glucosylceramide (GlcCer) 
from ceramide, inhibits MDR1 gene expression to reduce P-glycoprotein (P-gp) and reverse 
drug resistance.61 During the development of drug resistance, GlcCer accumulation was also 
observed.135,136 In cisplatin-resistant melanoma cells, the combination of cisplatin with FTY720, 
an agonist to S1PRs except for S1PR2, can reduce cell proliferation and induce cell death.137  
At the same time, the combination of FTY720 and cisplatin also decrease PI3K, Akt, and EGFR 
expression levels, critical proteins for cell survival.137,138 This experiment, once again, 
demonstrates the importance of endogenous S1P in cancer cells that have developed 
chemotherapy resistance.137,138  
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In addition, overexpression of sphingosine kinases, which are essential for ceramide 
conversion into S1P, is related to chemo-resistance in many cancers. 134,139,140  For example, 
in breast cancer MCF-7 cells, overexpression of SK1 results in increased resistance to 
doxorubicin, tamoxifen and necrosis factor.134,139 In non-small cell lung carcinoma cells, 
overexpression of SK2 has been related to gefitinib resistance.140  
 
3 Hypothesis and Objectives 
Sphingosine-1-phosphate (S1P), a pleiotropic lysophospholipid mediator, can regulate 
S1P receptor (S1PR)-dependent or S1PR-independent cell proliferation, migration, survival, 
and differentiation.91,95 Previous studies from our laboratory have shown that exogenously 
administered S1P can cause cell death in the breast cancer cell lines, MDA-MB-231 and MCF-
7, in a concentration-dependent way.70,141 Based on the pro-proliferation functions of S1PR1 on 
the cell surface, we assume that the reason for low concentrations of S1P to induce cell 
proliferation is due to the activation of this receptor. Thus, blocking S1PR1 signaling via ligand 
saturation would be effective in decreasing cell proliferation. 
 
Moreover, results in our lab have also shown that exogenous S1P enhances the 
cytotoxic effect of docetaxel, doxorubicin, and cyclophosphamide towards MDA-MB-231 and 
MDA-MB-361 cells.133 Based on the evidence, we hypothesize that S1P or S1PR1 antibody can 
enhance the cytotoxic effect of carboplatin towards MCF-7, SK-BR-3, and MDA-MB-231 cells.   
 
3.1 Hypothesis 
I. S1PR1 antibody enhances S1P cytotoxicity against breast cancer cells by blocking 
S1PR1 on the cell surface. 
II. S1P and S1PR1 antibody in combination can enhance the cytotoxic effect of anti-
cancer drug, carboplatin. 
 
3.2 Objectives 
I. Assess the cytotoxic effects of gradient concentrations of S1PR1 antibody alone and 
in combination with exogenous S1P against MCF7, SK-BR-3 and MDA-MB-231 cell lines. 
  
 
25 
II. Assess the cytotoxic effect of S1P, S1PR1 antibody and carboplatin in pairs on breast 
cancer cell lines MCF-7, SK-BR-3, and MDA-MB-231. 
 
4 Methods 
4.1 Materials 
Sphingosine-1-phosphate, carboplatin, MTT(3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide) were purchased from Sigma-Aldrich (Oakville, ON, Canada). 
S1PR1 antibody was purchased from Abcam (Cambridge, MA, US). Penicillin solution was 
purchased from Sigma Life Science (Kansas City, MO, USA). Leibovitz’s L-15 media, Eagle’s 
Minimum Essential media, McCoy’s 5a Medium Modified and Fetal Bovine Serum (FBS) were 
purchased from American Type Culture Collection (ATCC) (Manassas, VA, USA). 0.25 % 
Trypsin EDTA, bovine insulin and human epidermal growth factor were purchased from Sigma 
Life Science. CellTox™ Green Cytotoxicity Assay kit was from Promega (Madison, WI, 
USA). Cell Cytotoxicity Assay kit-colorimetric from Abcam (Cambridge, MA, USA). 
 
Cell lines: MDA-MB 231 cells (source: human breast adenocarcinoma, derived from 
pleural effusion), MCF-7 cells (source: human breast adenocarcinoma, derived from pleural 
effusion) and the SK-BR-3 cells (source: human mammary gland; breast) were purchased from 
ATCC. 
 
4.2 Cell culture 
According to the ATCC protocol (Table 4), MCF-7, SK-BR-3, and MDA-MB-231 cell lines 
were cultured in 75 cm2 flasks. MDA-MB-231 cells were cultured in Leibovitz’s L-15 medium 
supplemented with 10% FBS and 1% penicillin under 100% air without CO2. MCF-7 cells were 
cultured in Eagle’s Minimum Essential Medium supplied with 0.01 mg/mL bovine insulin, 10% 
FBS and 1% penicillin. SK-BR-3 cells were cultured in McCoy’s 5a Medium Modified with 10% 
FBS and 1% penicillin. MCF-7 and SK-BR-3 cells were cultured in 95% air and 5% CO2. Cell 
culture medium was changed every 2-3 days. 
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Table 3: The cell culture conditions for different breast cancer cell lines used in the 
experiments 
Cell line 
Receptor 
Expression Source Culture Medium 
Incubation 
condition 
Molecular 
Classification 
ER PR HER2 
MCF-7  √ √  — 
Pleural 
Effusion 
MEM, 10%FBS, 
0.01mg/mL insulin 
5%CO2, 
37℃ 
Luminal A 
SK-BR-3 — —  √ 
Pleural 
Effusion 
McCoy 5a medium, 
10%FBS 
5%CO2, 
37℃ 
HER2 
MDA-MD-231 — — — 
Pleural 
Effusion 
L-15, 10%FBS 
No CO2, 
37℃ 
Normal breast-
like 
MEM: Eagle's minimum Essential Medium; L-15: Leibovitz's L-15 medium 
 
4.3 Drug preparation 
Carboplatin powder was diluted with ddH2O to get a stock solution 27 mM and sterilized 
by pressing through a 0.20 µm filter. Final carboplatin dilutions of 4.2 – 1,080 µM were used in 
the combination experiments.  
 
In assessing the IC50 value of carboplatin in three breast cancer cell lines, carboplatin 
powder was diluted with corresponding growth medium. Final carboplatin dilution of 1.95 -1,000 
µg/mL for MCF-7 cell line, 0.98 -1,000 µg/mL for SK-BR-3 cell line, and 7.8 – 2,000 µg/mL for 
MDA-MB-231 cell line. New solutions were made for each experiment. 
 
To dissolve the S1P powder, methanol with 120 mg/mL polyethylene glycol (PEG) was 
prepared and S1P powder was diluted with methanol (120 mg/mL PEG) to obtain a stock 
solution of 2.64 mM. Final concentrations of 0.08 µM – 10 µM were made immediately before 
use. 
 
4.4 Toxicity assay 
4.4.1 Assess the toxic effect of S1PR1 antibody  
Depending on the particular cellular process of interest, different toxicity assays can be 
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used. In this project, two different toxicity assays were used – CellTox™ Green Cytotoxicity 
assay and MTT assay to assess the cytotoxicity of cells. The CellTox™ Green Cytotoxicity 
assay uses a proprietary asymmetric cyanine dye (CellTox™ Green Dye) which only binds to 
the dead cells’ DNA. Therefore, the fluorescence signal is proportional to the cytotoxicity at 
485/510 nm excitation source and 520 – 530 nm emission.142 The MTT assay can assess cell 
viability. The principle of MTT assay is that the NADH, which is a coenzyme in all living cells, 
could reduce MTT to crystal and insoluble purple product – formazan. Therefore, the quantity 
of formazan is presumably directly proportional to the number of viable cells.  
 
4.4.1.1 Using CellTox™ Green Cytotoxicity assay 
To assess the cytotoxic effect of S1PR1 antibody with CellTox™ Green Cytotoxicity assay 
kit, I seeded MCF-7 cells, MDA-MB-231 cells and SK-BR-3 cells at a density of 8,000 cells/well 
into 96-well plates. After 24 h, the medium was changed with medium containing 2 µL/mL green 
dye. Cells were treated with S1PR1 antibody. After 12 h, 18 h, 24 h, 48 h, 72 h, a Biotek 
microplate reader was used to quantitatively measure the dye’s fluorescence signal at 
485/510nm excitation source and 520 – 530 nm emission. The percentage of cell cytotoxicity 
was calculated using the formula: 
%Cell cytotoxicity = 
𝐸𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡−𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝑐𝑒𝑙𝑙 𝑑𝑒𝑎𝑡ℎ−𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙
× 100% 
 
4.4.1.2 Using MTT assay 
MCF-7 cells, MDA-MB-231 cells, and SK-BR-3 cells were seeded at a density of 8,000 
cells/well into 96-well plates. After 24h, cells were treated with S1PR1 antibody (16 – 4,000 
ng/mL). After 24 h (only for SK-BR-3), 48 h, or 72 h, the medium was replaced to medium with 
MTT (0.5 mg/mL). After treatment with MTT, the absorbance was measured at 570 nm with 
Biotek microplate reader. The percentage of viable cells was calculated using the formula: 
%Cell viability = 
𝑂𝐷(𝑠𝑎𝑚𝑝𝑙𝑒)− 𝑂𝐷(𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)
𝑂𝐷 (𝑣𝑒ℎ𝑖𝑐𝑙𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)−𝑂𝐷(𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑) 
× 100% 
 
4.4.2 Assess the IC50 values of carboplatin 
The MTT assay was performed to determine the IC50 value for MCF-7, SK-BR-3, and 
MDA-MB-231 cell lines. In brief, cells were seeded at 8,000 cells/well in 96-well plates. After 24 
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h, media was removed and new media containing carboplatin (1.95 – 1,000 µg/mL for MCF-7 
cell line, 0.98 – 1,000 µg/mL for SK-BR-3 cell line, and 7.8 – 2,000 µg/mL for MDA-MB-231 cell 
line) was added. After 48 h or 72 h, the medium was replaced with MTT (0.5 mg/mL). After 
treatment with MTT, the absorption was measured at 570 nm using a Biotek microplate reader. 
The percentage of viable cells was calculated using the formula: 
%Cell viability = 
𝑂𝐷(𝑠𝑎𝑚𝑝𝑙𝑒)− 𝑂𝐷(𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑)
𝑂𝐷 (𝑣𝑒ℎ𝑖𝑐𝑙𝑒 𝑐𝑜𝑛𝑡𝑟𝑜𝑙)−𝑂𝐷(𝑏𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑) 
× 100% 
Concentration-response curves were drawn. The IC50 values were determined by using 
the four-parameter nonlinear regression equation with variable slope in GraphPad Prism 
(GraphPad Prism 6.0 software, La Jolla, CA).  
 
4.4.3 Assess the cytotoxicity of S1P, S1PR1 antibody, and carboplatin in pairs 
MCF-7 cells, MDA-MB-231 cells and SK-BR-3 cells were seeded at a density of 8,000 
cells/well into different 96-well plates. After 24 h, cells were treated with S1PR1 antibody (80 or 
4,000 ng/mL) combining with S1P (0.08 – 10 μM), S1P (0.08 – 10 μM) combined with 
carboplatin (4.2 – 1,080 μM), or carboplatin (4.2 – 1,080 μM) combined with S1PR1 antibody 
(80 or 4,000 ng/mL). After 48h and 72h, the absorption was measured following the MTT 
protocol mentioned above.  
 
4.5 Data analysis 
Except for the experiments on determining the IC50 value of carboplatin, all results for 
toxicity assays were pooled and represented as mean values ± standard deviation. Data were 
presented as histograms. Two-way ANOVA with Sidak analysis was used to analyze the results. 
Significance was set at P ≤ 0.05. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. 
 
5 Results and discussion 
5.1 S1PR1 antibody exhibited cytostatic in breast cancer cells 
The antitumor effect of S1PR1 antibody against breast cancer cells was evaluated in 
three frequently used human breast cancer cell lines, MCF-7, SK-BR-3, and MDA-MB-231, 
using both MTT assay and CellTox Green Cytotoxicity Assay. MCF-7 (luminal A subtype) 
represents breast cancer that is amenable to hormone therapy and is less invasive compared 
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with SK-BR-3 and MDA-MB-231 cells.143 SK-BR-3 (HER2 subtype) cell line represents those 
that can respond to targeted therapy.143 MDA-MB-231 (triple-negative subtype) cell line 
represents the breast cancer that is more biologically aggressive and often has a poor 
prognosis.143 Although the binding affinity of this antibody to S1PR1 is not reported, the 
manufacturer recommended a final concentration of 200 ng/mL - 2,000 ng/mL for Western Blot 
and 1,000 ng/mL – 4,000 ng/mL for Flow Cytometry studies.  Therefore, we used concentration 
of 16 – 4,000 ng/mL in both assays.   
 
S1PR1 antibody alone showed cytostatic effect on the three human breast cancer cell 
lines in a concentration- and time-dependent manner, although the cell lines responded 
differently against S1PR1 antibody and the response was mild. In MTT assay (Figure 9), S1PR1 
antibody decreased the cell viability at concentrations above 500 ng/mL in MCF-7 cells. Up to 
40% reduction of cell viability was observed in MCF-7 after exposing to 4,000 ng/ml S1PR1 
antibody for 48 h. Comparing 48 h with 72 h exposure time for 500, 1,000, 2,000 and 4,000 
ng/ml S1PR1 antibody treatments, respectively, the cell viability was reduced more at 48 h. At 
the range of 16 – 4,000 ng/mL, the maximum effect of ~ 10% cell viability reduction was 
achieved at the concentration of 4,000 ng/mL after treating for 72 h in SK-BR-3 cells. Prolonged 
exposure did not enhance the effect of S1PR1 antibody on MCF-7 cells and SK-BR-3 cells. 
Meanwhile, the cell growth of MDA-MB-231 cells was promoted by S1PR1 antibody at low 
concentrations (16 - 500 ng/mL) while it was inhibited at high concentrations (1,000 - 4,000 
ng/mL). At low concentrations (16 – 500 ng/ml) of S1PR1 antibody, the percentage of living cells 
exhibited a bell-shaped dose-response relationship. The maximum promoting effect of cell 
growth (~ 10% increase in cell viability) was at 125 ng/mL S1PR1 antibody for 72 h; whereas 
within the range of the given concentrations, the maximum inhibiting effect on cell growth (~ 
27% decrease in cell viability) was at a concentration of 4,000 ng/mL S1PR1 antibody for 72 h. 
Collectively, only at high concentrations (above 1,000 ng/mL), the S1PR1 antibody achieves 
robust cytostatic effect on these three cell lines, which is consistent with literature evidence.144 
As cell viability was reduced after exposing to S1PR1 antibody, we conclude that the commercial 
S1PR1 antibody we bought is functionally effective. 
 
As shown in Figure 10, S1PR1 antibody did not cause a cytotoxic effect in SK-BR-3 cells 
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as examined with the CellToxTM Green Cytotoxicity assay while only ~ 10% cytotoxicity was 
observed in MDA-MB-231 cells at the concentration of 4,000 ng/mL S1PR1 antibody after 72 h. 
We speculated that the cytotoxicity might be caused by the differences of S1PR1 expression 
and internalization between the two cell lines.  However, we could not completely rule out the 
possibility that a different antigen possesses a fragment of sequence highly homologous to the 
epitope used in producing the S1PR1 antibody and binds S1PR1 antibody in the MDA-MB-231 
cells. In addition, a bell-shape dose response relation between S1PR1 antibody at low 
concentration and percentage living cells was observed in MDA-MB-231 cells. We speculate 
that this was caused by cellular production of S1P when S1PR1 was not completely blocked by 
its antibody. A similar bell-shape dose-response was also observed in MCF-7 cells at low 
concentrations of S1P (0.03 – 2 M) in the previous study.141 As mentioned above, the MTT 
assay, where MTT can be reduced to formazan by coenzyme in living cells, is used to measure 
the cell viability. The CellToxTM Green Cytotoxicity assay, where the green dye can only bind to 
DNA of dead cells, is used to estimate the cell death. Therefore, due to the experimental results 
observed from both detection methods, we consider that the effect on cell growth of S1PR1 
antibody on the MCF-7, SK-BR-3 and MDA-MB-231 cells is likely via the inhibition of cell growth 
(cytostatic effect).  
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Figure 9. Toxic effect of S1PR1 antibody against MCF-7, SK-BR-3, and MDA-MB-231 
cells. Cells were treated with different concentrations of S1PR1 antibody (16 – 4000 ng/mL) for 
48 h and 72 h. PBS was used as vehicle control. MTT Assay was performed to determine the 
percent cell viability. Results are presented from triplicate assays on three different occasions. 
Two-way ANOVA with Sidak analysis was used to analyze the significance between cells 
treated with different concentration of S1PR1 antibody and cells treated with vehicle control. 
The data are reported as mean ± SD (N=3), significance was set as P ≤ 0.05. Note: *, p ≤ 0.05; 
**, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001. 
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Figure 10. The cytotoxic effect of S1PR1 antibody on MDA-MB-231 and SK-BR-3 cells 
evaluated by CellTox™ Green Cytotoxicity Assay. Cells were exposed to S1PR1 antibody (0-
4000 ng/ml) for 48 h and 72 h. PBS was used as vehicle control. Results are presented from 
duplicate replications on two different occasions. Two-way ANOVA with Sidak analysis was 
used to analyze the significance between cells treated with different concentration of S1PR1 
antibody and cells treated with vehicle control. The data are reported as mean ± SD (N=2), 
significance was set as P ≤ 0.05. Note: *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001. 
 
Taken together, the results indicate that these three breast cancer cell lines react 
differently to S1PR1 antibody. One reason might be gene expression differences within these 
three cell lines. As shown in Figure 11, different subtypes of breast cancer cells have different 
cellular genotypes. For example, phosphatase and tensin homolog (PTEN), which is a tumor 
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suppressor gene that prevents cells from dividing uncontrollably, exists in wild-type in these 
three cell lines. Estrogen receptor (ER), which acts as a transcription factor after binding with 
estrogen, is overexpressed in MCF-7 cells while is normally expressed in both SK-BR-3 and 
MDA-MB-231 cells. PIK3CA, which encodes PI3K protein, is mutated in MCF-7 cells but normal 
in SK-BR-3 and MDA-MB-231 cells. Human epidermal growth factor receptor 2 (HER2 or 
ERBB2), an oncogene that plays a vital role in certain types of cancer progression, is 
overexpressed in SK-BR-3 cells, but exists in wild-type in MCF-7 and MDA-MB-231 cells. 
Furthermore, protein expression of the genes mentioned above, are the downstream reactors 
of S1PR1. Thus, MCF-7, SK-BR-3, and MDA-MB-231 reacted differently to the exposure of 
S1PR1 antibody. Moreover, because of the genotype difference, the metabolic rates of the 
S1PR1 antibody in these two cell lines might be different. 
 
  
 
34 
 
Figure 11. The clustering results of gIC50 values of 19 compounds (rows) on 16 breast 
cancer cell lines (columns) (P = 0.0009, Fisher's exact test). It shows that cellular genotype is 
a strong driver for different breast cancer cells reacting to compounds. Green and red cells 
represent cell lines with lower and higher gIC50 values, respectively, whereas grey cells indicate 
missing data.145 Permission to reproduce this is granted by American Association for Cancer 
Research. 
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The second reason for the different responses of the three cell lines to S1PR1 antibody 
is that the expression level of S1PR1 is different in these cell lines. The expression levels of 
S1PR1 in breast cancer tissues and breast cancer cells are ambiguous at present time; with 
results varying dramatically from different researchers. Information from The Human Protein 
Atlas database (HPA) show that the expression level of S1PR1 in breast cancer tissues is 
downregulated compared to normal breast tissues. As shown in Table 4, the RNA-seq data of 
normal breast tissues was generated by the Genotype-Tissue Expression project from 214 
tissue samples. The data were presented as average RPKM (reads per kilobase per million 
mapped reads). The RNA-seq data of breast cancer tissues were generated by The Cancer 
Genome Atlas from 1075 tissue samples. The data were presented as average FPKM (number 
Fragments per Kilobase of exon Million reads). Because RPKM is calculated from single-end 
RNA-seq results and FPKM is calculated from the paired-end RNA-seq, FPKM is equal to half 
value of RPKM. Therefore, we can see that the expression level of S1PR2 and S1PR3 did not 
change much in breast cancer tissues compared to normal breast tissues, S1PR1 reduced 
tremendously in breast cancer tissues. In addition, from The Human Protein Atlas, the 
expression level of S1PR1 in MCF-7 and SK-BR-3 cells was downregulated and that the TPM 
(transcripts per kilobase million) values of S1PR1 in these two cell lines were closed to zero. 
However, as shown in Figure 12, another study shows that the expression of S1PR1 was 
upregulated on 25 patient-derived breast cancer tissues and four breast cancer cell lines (MDA-
MB-231, MCF-7, T-47D and BT-474) compared with normal breast tissues and breast cells, 
respetively.146 From the results in this study, it is implied that the relative S1PR1 expression 
level was higher in MDA-MB-231 cells than in MCF-7.146 This may be the reason that in my 
experiment, exposed to 500 ng/ml S1PR1 antibody for 48 h can cause about 20% cell viability 
reduction in MCF-7 cells while in MDA-MB-231 cells, only 15% cell viability reduction was 
observed after 48 h exposing to 2,000 ng/mL S1PR1 antibody. In order to further demonstrate 
the relationship between the expression level of S1PR1 antibody in breast cancer cells and the 
antitumor effect of S1PR1 antibody, the expression status of S1PR1 in different breast cancer 
cell lines should be further tested. 
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Table 4. The expression levels of S1PRs on normal breast and breast cancer tissues 
 Normal breast tissues Breast cancer tissues 
Average RPKM Average FPKM 
S1PR1 67.7 8.0 
S1PR2 2.4 4.3 
S1PR3 2.9 6.2 
 
 
Figure 12. The expression level of S1PR1 was detected by qRT-PCR. Expression of 
S1PR1 was upregulated in breast cancer tissues samples from 25 patients compared with 
normal breast tissues, and in breast cancer cells (MDA-MB-231, MCF-7, T-47D and BT-474) 
compared with normal breast cells (HBL-100).  *, p ≤ 0.05; **, p ≤ 0.01.146 Permission to 
reproduce this is granted by Medical and Pharmacology Sciences. 
In fact, many S1PR1 agonists and antagonists have been developed in recent years for 
cancer treatment. For example, S1PR1 antagonists were shown to be able to inhibit tumor 
angiogenesis in vivo and enhance therapeutic efficacy of doxorubicin.18,120 But adverse effects 
always appear during the treatments. For example, fingolimod (FTY720), an antagonist of all 
S1PRs except S1PR2, has been clinically approved for the treatment of relapsing and remitting 
multiple sclerosis.93 Use of fingolimod has clinical adverse effects – significant transient 
bradycardia because of its effect on cardiac S1PR3.93 In addition, FTY720P, the active 
metabolite of FTY720, is a functional antagonist through promoting internalization of S1PR1. 
However, persistent signaling, function as agonist of S1PR1, was observed after short time 
exposure to FTY720P.93,147 Therefore, monoclonal S1PR1 antibody is used in my experiment 
to avoid the confusing functions of FTY720P. Using S1PR1 antibody may be associated with 
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fewer side effects compared with current agonists and antagonists of S1PRs such as fingolimod. 
 
Results show that S1PR1 antibody caused cytostasis in the three breast cancer cell lines 
but due to the diverse functions of S1PR1, the mechanism of the inhibition effect of S1PR1 
antibody on cell growth in breast cancer cells is still unrevealed. Blocking S1PR1 on the cell 
surface with its antibody can lead to inhibition of PI3K, PLC and Ras GTPase protein and their 
downstream pathways, which involve numerous proteins and molecules. For example, blocking 
S1PR1 with its antibody can lead to inhibition of ERK protein and upregulation of pro-apoptosis 
protein Bim, finally inducing cell apoptosis by activating caspase 3 protein.148 In addition, it is 
possible that after blocking S1PR1 with its antibody on the cell surface, S1P produced by the 
cells themselves can bind to S1PR2 to reduce cell viability or through the influx into cells and 
act as a second messenger to elude downstream reactions. 
 
5.2 S1P activity was not enhanced by S1PR1 antibody in breast cancer cells 
To assess the cytotoxic effects of S1P combined with S1PR1 antibody in MCF-7, SK-BR-
3, and MDA-MB-231 cells, MTT assay and CellToxTM Green Cytotoxicity assay were performed. 
First, MTT assay was carried out at fixed S1PR1 antibody concentration of 80 ng/mL with 
different concentrations of S1P in the three aforementioned cell lines. As shown in Figure 13, 
combination with 80 ng/mL S1PR1 antibody did not enhance the effect of S1P on cell viability 
in MCF-7 cells. Co-administration with 4,000 ng/mL S1PR1 antibody increased cell viability 
about 10% when comparing with 48-hour treatment of S1P alone at 10 μM, so as with 72-hour 
treatment. Compared with cells treated with 10 μM of S1P, no significant reduction on cell 
viability was observed in SK-BR-3 cells treated with 4,000 ng/mL S1PR1 antibody and 10 μM 
of S1P for 24 h. However, co-administration of 4,000 ng/mL S1PR1 antibody decreased the cell 
viability by almost 20% (p ≤ 0.0001) after 48 h treatment comparing with 10 μM of S1P alone. 
At 72 h of treatment, the co-administration of S1PR1 antibody reduced the cell viability by 
approximately 10%, but this decrease is not statistically significant. For the MDA-MB-231 cell 
line, S1P alone and combined with S1PR1 antibody did not show any significant difference with 
each other. Subsequently, we evaluated the cytotoxic effect of the combination of S1P at two 
fixed concentrations (1 and 10 μM) with S1PR1 antibody at various concentrations in the three 
cell lines using the CellToxTM Green Cytotoxicity Assay. S1PR1 antibody combined with 10 μM 
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S1P were used to evaluate whether there could be any synergistic/additive effect. 10 μM of 
S1P was chosen based on the previous studies in our lab. Results from our lab showed that 
S1P selectively induced cell apoptosis in breast cancer MCF-7 cells and exhibited synergistic 
effect with chemotherapy drugs docetaxel, doxorubicin and cyclophosphamide in breast cancer 
cell lines MCF-7 and MDA-MB-361 at a concentration higher than 1 μM, especially at 10 
μM.70,141 As shown in Figures 14, 15 and 16, no significant differences in cell death were 
observed in MCF-7, SK-BR-3 and MDA-MB-231 cells as compared to negative control when 
S1P and S1PR1 antibody were co-administered. In conclusion, these results suggest that 
S1PR1 antibody did not enhance the cytotoxic effect of S1P towards the MCF-7 and MDA-MB-
231 cells. For the SK-BR-3 cells, S1PR1 antibody showed marginal enhancement on the 
cytotoxic effects of S1P. 
 
We hypothesized that high concentration of S1P (10 μM) could block S1PRs on the cell 
surface and cause cell death through the intracellular function of S1P. S1PR1 antibody may 
prolong the cytotoxic effect of S1P in SK-BR-3 cells by preventing the binding of S1P to the 
S1PR1 on the cell surface even after it is degraded to lower concentrations. However, further 
exploration is still needed to confirm this hypothesis. 
 
The combination of 10 μM S1P and 4,000 ng/mL S1PR1 antibody affects the cell growth 
of MCF-7, SK-BR-3 and MDA-MB-231 cells differently. One reason for this is the differences of 
gene expression in these three cell lines, similar as the cause of cell growth effect for S1PR1 
antibody. Another reason might be the different degradation rates of S1P in these three cell 
lines, but the exact values are still unclear. In this study, cell viability reduction was observed 
when MCF-7 and MDA-MB-231 cells were treated with 10 μM of S1P for both 48 h and 72 h, 
while no cytotoxicity was detected in SK-BR-3 cells. A previous study of our lab showed that 1 
μM S1P was degraded within 24 h in SK-BR-3 cells. It is possible that the degradation rate of 
S1P in the MCF-7 and MDA-MB-231 is slower as compared with that in the SK-BR-3 cells. 
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Figure 13. The effect of S1P combined with S1PR1 antibody on MCF-7, SK-BR-3 and 
MDA-MB-231 cells were examined using MTT assay. Cells were treated with S1PR1 antibody 
(80 or 4,000 ng/mL) combined with S1P (0.08 – 10 μM) for up to 72h. DMSO < 1% and PBS 
were used as vehicle control. Results are presented from triplicate experiments on different 
occasions. Two-way ANOVA with Sidak analysis was used to analyze the significance between 
cells treated with S1P combined with S1PR1 antibody and cells treated with S1P alone. The 
data are reported as mean ± SD (N=3), significance was set as P ≤ 0.05. Note: *, p ≤ 0.05; **, 
p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001. 
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Figure 14. Cytotoxic effect of S1P in combination with S1PR1 antibody on MCF-7 cells 
with CellTox™ Green Cytotoxicity Assay. Cells were exposed to S1P (0.1 μM, 1 μM, or 10 μM) 
with S1PR1 antibody (8 – 80 ng/ml) for up to 72h.  DMSO < 1% and PBS were used as vehicle 
control. Results were from duplicate independent experiments. Two-way ANOVA with Sidak 
analysis was used to analyze the significance between cells treated with S1P combined with 
S1PR1 antibody and cells treated with S1P alone. The data are reported as mean ± SD (N=2), 
significance was set as P ≤ 0.05. Note: *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001. 
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Figure 15. Cytotoxic effect of S1P in combination with S1PR1 antibody on SK-BR-3 cells 
with CellToxTM Green Cytotoxicity Assay. Cells were exposed to S1P (0.1 μM, 1 μM, or 10 μM) 
with S1PR1 antibody (8 – 80 ng/ml) for up to 72h.  DMSO < 1% and PBS were used as vehicle 
control. Results were from duplicate independent experiments. Two-way ANOVA with Sidak 
analysis was used to analyze the significance between cells treated with S1P combined with 
S1PR1 antibody and cells treated with S1P alone. The data are reported as mean ± SD (N=2), 
significance was set as P ≤ 0.05. Note: *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001. 
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Figure 16. Cytotoxic effect of S1P in combination with S1PR1 antibody on MDA-MB-231 
cells with CellToxTM Green Cytotoxicity Assay. Cells were exposed to S1P (0.1 μM, 1 μM, or 10 
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μM) with S1PR1 antibody (8 – 80 ng/ml) for up to 72h.  DMSO < 1% and PBS were used as 
vehicle control. Results were from duplicate independent experiments. Two-way ANOVA with 
Sidak analysis was used to analyze the significance between cells treated with S1P combined 
with S1PR1 antibody and cells treated with S1P alone. The data are reported as mean ± SD 
(N=2), significance was set as P ≤ 0.05. Note: *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 
0.0001. 
 
5.3 IC50 value of carboplatin 
The cytotoxic effect of carboplatin was determined in breast cancer cell lines SK-BR-3 
and MDA-MB-231 using the MTT assay. As expected, there was a dose-dependent cell killing 
effect. The IC50 of carboplatin was determined to be 376 μM (48h) and 265 μM (72 h) against 
MCF-7 cells, 80.0 μM (48 h) and 30.6 μM (72 h) against SK-BR-3 cells, and 834 μM (48 h) and 
294 μM (72 h) against MDA-MB-231 cells, respectively. Previous studies have shown that the 
IC50 of carboplatin was 62.19 μM (72h) against MCF-7 cells149, 45.43 μM (72h) against SK-BR-
3 cells149, and 269 μM (72h) against MDA-MB-231 cells150. The IC50 values of carboplatin of 
SK-BR-3 and MDA-MB231 cells in my experiment were quite close with the published 
results.149,150 However, the values of the MCF-7 cells are quite different – 265 μM from my 
experiment and 62.19 μM (72h) from the published results. The divergence may be due to the 
genetic drift and phenotype drift between the MCF-7 cells in my experiment and the one used 
in publication, the differences in preparing carboplatin solutions, the methods applied to 
calculate the IC50 value or the range of concentrations used to assess the IC50 of carboplatin 
between my experiment and the publication. Nevertheless, the IC50 value of carboplatin in these 
three cell lines is extremely high compared to the reported IC50 of carboplatin towards several 
cell lines derived from ovarian cancer patients, which is around 1 μM for pre-chemotherapy cell 
lines and 5 μM for post-chemotherapy cell lines.151  This implies that carboplatin might not be 
the first choice for treating luminal A, HER2 or triple-negative subtype breast cancer, although 
it is approved for advanced-stage breast cancer. Based on the IC50 values, 6 to 7 concentrations 
were decided in further combination experiments with S1P or S1PR1 antibody.  
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 IC50 (95% CI) (µM) 
Cell types MCF-7 SK-BR-3 MDA-MB-231 
48h 376 (219.8-644.5) 80 (72.8-87.8) 834 (738.5-942.6) 
72h 265 (221.9-316.4) 30.6 (28.0-33.3) 394 (355.3-436.4) 
 
Figure 17. Dose responses curves show IC50 of carboplatin on reduction of breast cancer 
cell lines MCF-7, SK-BR-3, and MDA-MB-231 cell viability. Error bars represent mean values ± 
standard deviation of three replicates on three different occasions. PBS was used as vehicle 
control. 
 
5.4 S1PR1 antibody sensitized the breast cancer cells to carboplatin at high 
concentrations 
In order to assess the effects of co-administrated S1PR1 antibody with carboplatin in 
MCF-7, SK-BR-3 and MDA-MB-231 cells, I evaluated the effect on cell viability of carboplatin 
alone and combined with S1PR1 antibody using the MTT assay. Two S1PR1 antibody 
concentrations were used in this experiment. First, 80 ng/mL S1PR1 antibody was chosen to 
determine whether there was synergistic effect between carboplatin and S1PR1 antibody. 
Compared to cells treated with carboplatin and cells treated with carboplatin combined with 80 
ng/ml S1PR1 antibody, no significant difference was observed for the effect on cell viability in 
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MCF-7, SK-BR-3 and MDA-MB-231 cells (Figure 18). Therefore, low concentrations of S1PR1 
antibody (such as 80 ng/mL) cannot enhance the cytotoxic effect of carboplatin in these three 
cell lines. Therewith S1PR1 antibody (4,000 ng/mL), which alone decreased cell viability in both 
SK-BR-3 and MDA-MB-231 cells, was tested in the SK-BR-3 and MDA-MB-231 cells in 
combination with carboplatin. Because of the shortage in funding, no experiments were 
conducted in the MCF-7 cells. For the SK-BR-3 and MDA-MB-231 cells, I chose a concentration 
of carboplatin significantly lower than the IC50 (4 μM for SK-Br-3 and 68 μM for MDA-MB-231), 
which does not impose any cytotoxicity to the cells.  The reason for this type of selection is to 
ensure that this research would lead to further in vivo and even clinically meaningful studies if 
the S1PR1 antibody indeed sensitized breast cancer cells to carboplatin as a recent study 
shows using FTY720 to block S1PR1 receptor on neuroblasma cells sensitizes cells to 
etoposide, a chemo-drug.152.  In addition, I chose a high concentration of carboplatin, 
significantly higher than the IC50 for these two cell lines (540 μM for SK-Br-3 and 1080 μM for 
MDA-MB-231). As shown in Figure 19, only marginal difference was observed after 48 h and 
72 h treatment with 4.2 µM carboplatin and 4.2 µM carboplatin combined with S1PR1 antibody 
in the SK-BR-3 cells. For the MDA-MB-231 cells, the co-administration of S1PR1 antibody and 
low concentration of carboplatin decreased the cell viability by more than 35% compared to 
carboplatin alone (p ≤ 0.0001). This suggested that 4,000 ng/mL S1PR1 antibody enhanced the 
cytotoxic effect of carboplatin.   
 
As shown in Figure 19, the enhancement effect of 4,000 ng/mL S1PR1 antibody on 
carboplatin is more notable in triple-negative subtype MDA-MB-231 cells than in HER2 subtype 
SK-BR-3 cells. This might due to the gene expression difference between these two cell lines. 
It is possible that 4,000 ng/mL S1PR1 antibody can enhance the cytotoxic effect of carboplatin 
in triple-negative breast cancer cells more obviously than other breast cancer subtypes. In order 
to demonstrate this conjecture, more triple-negative subtype cell lines should be used in the 
future studies. 
 
The enhanced cytotoxic effect of carboplatin by the S1PR1 antibody might be due to 
S1PR1 antibody interference with the SK1/S1P/S1PR1 signaling axis and suppression of the 
NF-B/IL-6/STAT3 loop in breast cancer cell lines, as observed for FTY720’s ability to sensitize 
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breast cancer cells to doxorubicin.18 In addition, co-administration of S1PR1 antibody with 
carboplatin may help to delay tumor recurrent and carboplatin drug resistance in breast cancer. 
In breast cancer, carboplatin was found to induce the expression of glutathione S-transferase 
omega 1 (GSTO1), which can catalyze the production of glutathione that contributes to drug 
resistance.153 Then GSTO1 can lead to calcium release to the cytoplasm.153 Through activation 
of STAT3 pathway, it can increase the expression of pluripotency factors and breast cancer 
stem cell enrichment, increasing chemo-resistance.153 At the same time, blocking S1PR1 with 
its antibody may inhibit the calcium release from endoplasmic reticulum, therefore, decreasing 
the chemo-resistance of carboplatin in breast cancer and improving the clinical outcome.  
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Figure 18. Toxic effect of carboplatin in combination with 80 ng/mL S1PR1 antibody on 
MCF-7, SK-BR-3, and MDA-MB-231 cells for 48 h or 72 h tested with MTT assay. Cells treated 
with solvent as a negative control. Results were from triplicate independent experiments. Two-
way ANOVA with Sidak analysis was used to analyze the significance between cells treated 
with carboplatin combined with S1PR1 antibody and cells treated with carboplatin alone. The 
data are reported as mean ± SD (N=3), significance was set as P ≤ 0.05. Note: *, p ≤ 0.05; **, 
p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001. 
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Figure 19. Toxic effect of carboplatin in combination with 4,000 ng/mL S1PR1 antibody 
on SK-BR-3 and MDA-MB-231 cells for 48 h or 72 h tested with MTT assay. Cells treated with 
solvent as a negative control. Results were from triplicate independent experiments. Two-way 
ANOVA with Sidak analysis was used to analyze the significance between cells treated with 
carboplatin combined with S1PR1 antibody and cells treated with carboplatin alone. The data 
are reported as mean ± SD (N=3), significance was set as P ≤ 0.05. Note: *, p ≤ 0.05; **, p ≤ 
0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001. 
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5.5 S1P could not enhance the cytotoxic effect of carboplatin in breast cancer 
cells 
The effects of carboplatin alone and combined with S1P on cell viability in MCF-7, SK-
BR-3 and MDA-MB-231 cells were assessed using the MTT assay. The concentrations of S1P 
were 1 μM and 10 μM in this experiment. Normally, the concentration of S1P in plasma is around 
0.2 – 0.9 μM. Therefore, 1 μM concentration, which is close to the normal plasma level of S1P, 
was chosen. Concentration of 10 μM was used because that S1P selectively induced cell 
apoptosis in breast cancer cells MCF-7 and exhibited synergistic effects with chemotherapy 
drugs towards breast cancer MCF-7 and MDA-MB-361 cells at a concentration higher than 1 
μM, especially at 10 μM 70,141. As shown in Figure 20, neither 1 μM nor 10 μM of S1P was able 
to sensitize MCF-7, SK-BR-3 and MDA-MB-231 cells to carboplatin treatment.  However, 10 
μM S1P decreased the cell viability of the MCF-7, SK-BR-3 and MDA-MB-231 cells by 
approximately 30%, 15% and 30%, respectively, at both 48 h and 72 h treatments.  For the 
three cell lines, when carboplatin concentration was less than the IC50 values, the effect of the 
co-administration of 10 μM S1P and carboplatin on cell viability was dominated by S1P.  
Whereas the carboplatin concentration was increased above the IC50 values, the effect of the 
co-administration of S1P (concentration: 10 μM) and carboplatin on cell viability was controlled 
by carboplatin.  Therefore, contrary to our previous studies that S1P can increase the cytotoxic 
activities of docetaxel, doxorubicin and cyclophosphamide, co-administration of high 
concentrations of S1P does not improve the cytotoxic activity of carboplatin. The reason for this 
is still unknown. Docetaxel, doxorubicin, cyclophosphamide and carboplatin have different 
mechanisms of killing cancer cells. Docetaxel is an anti-mitotic agent through stabilized 
microtubule154; doxorubicin is an anthracycline antibiotic that can intercalate into DNA and 
interrupt the function of topoisomerase--mediated DNA repair155; cyclophosphamide is a 
nitrogen mustard alkylating agent that prevents DNA synthesis and RNA transcription through 
forming complex with DNA; and carboplatin is a DNA alkylating agent that can covalently link 
to DNA bases and form DNA adducts. In order to find the mechanisms on how S1P enhances 
the cytotoxic effect of some agents used in chemotherapy, more chemotherapy drugs need to 
be assessed. 
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Figure 20. Percent cell viability of MCF-7, SK-BR-3 and MDA-MB-231 cells after 
exposure to carboplatin alone or combined with S1P. Cells were treated with S1P (0.08 – 10 
μM) combined with carboplatin (4.2 – 1080 μM). DMSO < 1% and PBS were used as vehicle 
control. Results were obtained in three independent experiments. Two-way ANOVA with Sidak 
analysis was used to analyze the significance between cells treated with carboplatin combined 
with S1P and cells treated with carboplatin alone. The data are reported as mean ± SD (N=3), 
significance was set as P ≤ 0.05. Note: *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001. 
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6 Limitations and conclusions 
In this study, we showed that the S1PR1 antibody exhibited cytostatic effects towards 
luminal A subtype MCF-7 cell line, HER2 subtype SK-BR-3 cell line, and triple-negative subtype 
MDA-MB-231 cell line.  Co-administration of 4,000 ng/mL of the S1PR1 antibody not only 
potentiated the cytotoxicity of carboplatin towards cell line MDA-MB-231 but also increased the 
anti-proliferative effect of S1P towards cell line SK-BR-3.  Furthermore, co-administration of 
S1P did not improve the response of the MCF-7, SK-BR-3 and MDA-MB-231 cells towards 
carboplatin treatment. 
 
There are, however, some limitations in this study. First, the cytotoxic effect of co-
administration of 4,000 ng/mL S1PR1 antibody with S1P and carboplatin, respectively, was not 
assessed in MCF-7 cells because of funding limitations. Second, only two different 
concentrations of carboplatin were used to assess the co-administration of 4,000 ng/mL S1PR1 
antibody on SK-BR-3 and MDA-MB-231 cells. Third, when assessing the effect of 4,000 ng/mL 
S1PR1 antibody and carboplatin, no 4,000 ng/mL S1PR1 antibody alone was tested at the same 
time to act as a negative control. Therefore, in the future, cytotoxicity assay should be 
conducted on different concentrations of carboplatin with 4,000 ng/mL S1PR1 antibody in these 
three cell lines, using carboplatin and 4,000 ng/mL S1PR1 antibody alone as controls.  
 
7 Future work 
The mechanisms of the cytostatic effect of S1PR1 antibody should be focused in the 
future. To discover the mechanism, the following questions should be studied. First, the 
expression levels of S1PRs on the cell surface should be compared with normal breast cells. 
This can be done by extracting different S1PRs mRNA from different breast cancer cells lines 
and normal breast cancer cells, then performing quantitative RT-PCR. Second, the subcellular 
localization of S1PRs inside the cells should be assessed. This can be done with the help of 
laser scanning confocal microscopy (LSCM). Third, it should be determined whether the 
cytostatic effect of S1PR1 antibody is related to S1PR2 and S1PR3 on the cell surface. Blocking 
S1PR1 with its antibody on the cell surface, S1P produced by the cells themselves can bind to 
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S1PR2 to reduce cell viability or through the influx into cells and act as a second messenger to 
elude downstream reactions. Thus, studies are needed to verify whether S1PR1 antibody would 
have effect on S1P-S1PR2 and S1P-S1PR3 signaling in human breast cancer cells. S1PR2 
antibody or antagonists such as JTE-01375 could be used to assess whether the cytostatic 
effect of S1P involves downstream reactions of S1PR2 on the cell surface. Fourthly, the 
synthetic rate and degradation rate of S1P should be assessed in breast cancer cells before 
and after treating S1PR1 antibody as it may affect the synthesis and degradation rate of S1P in 
breast cancer cells in vitro. 
 
In addition, aggressive breast cancer cell lines should be applied in the cytotoxic study 
of 4,000 ng/mL S1PR1 antibody combined with carboplatin. Because in the study, it shows that 
4,000 ng/mL S1PR1 antibody enhanced the cytotoxic effect of carboplatin in triple-negative 
subtype MDA-MB-231 cells and no enhancement was observed in HER-2 positive subtype SK-
BR-3 cells. Therefore, 4,000 ng/mL S1PR1 antibody may enhance the cytotoxic effect of 
carboplatin in the more aggressive breast cancer cell types such as triple-negative breast 
cancer subtype. In addition, co-administration of 4,000 ng/mL S1PR1 antibody with other 
chemo-drugs such as docetaxel, doxorubicin and cyclophosphamide can be tested in various 
breast cancer subtypes.  
 
Lastly, the gene expression profiles of normal breast cells and different breast cancer 
cell lines should be studied with the help of the Cancer Genome Project and the Cancer Cell 
Line Encyclopedia to link the relationship with gene expression and cell reaction against S1PR1 
antibody, carboplatin and these two combinations. Studying the gene expression profiles of 
normal breast cells and breast cancer cells can also help to explain why S1P can enhance the 
cytotoxic effect of docetaxel, doxorubicin and cyclophosphamide in MDA-MB-231 cells and 
MCF-7 cells, but it cannot enhance the cytotoxic effect of carboplatin. 
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